AtriCure, Inc. (ATRC)

Price$27.10

Value ScoreC

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-32.90%

Price vs S&P 500 (4W)3.13%

VGM Score53.54

Market Capitalization$1.37B

All Metrics

P/CF (Annual)23.94x

Book Value / Share (Quarterly)$9.71

P/TBV (Annual)4.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.39%

Cash Flow / Share (Quarterly)$0.94

Price vs S&P 500 (YTD)-39.65%

Gross Margin (TTM)75.61%

Net Profit Margin (TTM)-0.83%

EPS (TTM)$-0.10

10-Day Avg Trading Volume0.79M

EPS Excl Extra (TTM)$-0.10

Revenue Growth (5Y)20.95%

EPS (Annual)$-0.24

ROI (Annual)-2.04%

Gross Margin (Annual)74.98%

Net Profit Margin (5Y Avg)-3.03%

Cash / Share (Quarterly)$2.89

Revenue Growth QoQ (YoY)14.26%

ROA (Last FY)-1.75%

Revenue Growth TTM (YoY)15.01%

EBITD / Share (TTM)$0.00

ROE (5Y Avg)-3.67%

Operating Margin (TTM)-0.54%

Cash Flow / Share (Annual)$0.85

P/B Ratio2.79x

P/B Ratio (Quarterly)2.94x

Net Income / Employee (Annual)$-8,500

EV / Revenue (TTM)2.34x

Net Interest Coverage (TTM)-6.26x

ROA (TTM)-0.72%

EV / EBITDA (TTM)26961.88x

EPS Incl Extra (Annual)$-0.24

Current Ratio (Annual)3.96x

Quick Ratio (Quarterly)2.97x

3-Month Avg Trading Volume0.76M

52-Week Price Return-22.28%

EV / Free Cash Flow (Annual)30.61x

Revenue / Employee (TTM)$409,000

Tangible BV / Share (Quarterly)$8.81

P/S Ratio (Annual)2.57x

Asset Turnover (Annual)0.82x

52-Week High$43.18

Operating Margin (5Y Avg)-2.03%

EPS Excl Extra (Annual)$-0.24

CapEx CAGR (5Y)23.40%

Tangible BV CAGR (5Y)9.33%

26-Week Price Return-24.97%

Quick Ratio (Annual)2.87x

13-Week Price Return-10.59%

Total Debt / Equity (Annual)0.14x

Current Ratio (Quarterly)4.29x

Enterprise Value$1.29B

Revenue / Share Growth (5Y)17.94%

Asset Turnover (TTM)0.87x

Book Value / Share Growth (5Y)1.65%

Revenue / Employee (Annual)$395,900

Inventory Turnover (Annual)1.74x

Pretax Margin (Annual)-1.90%

Cash / Share (Annual)$3.36

3-Month Return Std Dev38.10%

Gross Margin (5Y Avg)74.88%

Net Income / Employee (TTM)$-3,400

ROE (Last FY)-2.33%

Net Interest Coverage (Annual)-1.91x

EPS Basic Excl Extra (Annual)$-0.24

P/FCF (TTM)24.73x

Receivables Turnover (TTM)8.20x

EV / Free Cash Flow (TTM)27.16x

Total Debt / Equity (Quarterly)0.14x

EPS Incl Extra (TTM)$-0.10

Receivables Turnover (Annual)8.42x

ROI (TTM)-0.83%

P/S Ratio (TTM)2.49x

Pretax Margin (5Y Avg)-2.88%

Revenue / Share (Annual)$11.19

Tangible BV / Share (Annual)$8.92

Forward P/E165.76x

Price vs S&P 500 (52W)-46.65%

Year-to-Date Return-31.50%

5-Day Price Return2.34%

EPS Normalized (Annual)$-0.24

ROA (5Y Avg)-2.77%

Net Profit Margin (Annual)-2.14%

Month-to-Date Return-2.06%

Cash Flow / Share (TTM)$-0.24

EBITD / Share (Annual)$-0.13

Operating Margin (Annual)-1.77%

LT Debt / Equity (Annual)0.13x

P/CF (TTM)21.32x

ROI (5Y Avg)-3.18%

LT Debt / Equity (Quarterly)0.12x

EPS Basic Excl Extra (TTM)$-0.10

P/TBV (Quarterly)3.24x

P/B Ratio (Annual)4.00x

Inventory Turnover (TTM)1.73x

Pretax Margin (TTM)-0.59%

Book Value / Share (Annual)$9.88

Price vs S&P 500 (13W)-18.85%

Beta1.24x

P/FCF (Annual)32.46x

Revenue / Share (TTM)$11.26

ROE (TTM)-0.95%

52-Week Low$25.36

vGradeC

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.00est. -0.06

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.27

4.07

4.06

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
ATRCAtriCure, Inc.	C	B	C	$27.10
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

AtriCure develops surgical solutions for treating atrial fibrillation, managing left atrial appendage, and alleviating post-operative pain in cardiac and thoracic procedures. Its product portfolio includes cryoablation, radiofrequency ablation, and nerve pain management technologies used in open-heart and minimally invasive surgical settings. The company sells through direct sales and distributors, with the majority of revenue from the United States.